Human Immunodeficiency Virus Clinical Trial
Official title:
Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique
Verified date | January 2017 |
Source | Ningbo No. 1 Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospect, randomized control trial to evaluate merits between flip and no flip technique in Shang Ring children circumcision.
Status | Completed |
Enrollment | 100 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 7 Years to 12 Years |
Eligibility |
Inclusion Criteria: - Aged between 7 years and 12 years(inclusive); - Must be accompanied by the parent or legally acceptable representative (LAR), who freely agrees with participation of the child into the study; - Must tolerate local anesthesia; - Must be in good general health; - Parent or LAR and if possible the client must be able to understand study procedures and requirements of study participation; - Parent or LAR must agree to return the client to the study site for the full schedule of follow-up visits after his circumcision; - Parent or LAR must agree the study staff to take photos during operation or follow-up if necessary, and - Parent or LAR must agree to provide the study staff with an address, phone number, or other locator information Exclusion Criteria: - Has a known allergy or sensitivity to lidocaine or other local anesthesia; - Takes a medication that would be a contraindication for elective surgery (e.g anticoagulant , steroid); - Has known bleeding/clotting disorder (e.g. hemophilia); - Has an active genital infection, anatomic abnormality or other condition(e.g. concealed penis, hypospadias, epispadia, micropenis); - Is currently participating in another biomedical research study; or - Participants under other condition (e.g. severe obesity, diabetes or sickle cell anemia) should be excluded from this study in the opinion of the surgeon. |
Country | Name | City | State |
---|---|---|---|
China | Ningbo NO.1 hospital | Ningbo | Zhejiang |
China | The Affiliated Hospital of Medical College, Ningbo University | Ningbo | Zhejiang |
Lead Sponsor | Collaborator |
---|---|
Ningbo No. 1 Hospital | The Affiliated Hospital of Medical College, Ningbo University |
China,
Barone MA, Awori QD, Li PS, Simba RO, Weaver MA, Okech JO, Aduda AO, Cherutich P, Muraguri N, Wekesa JM, Nyanchoka J, Perchal P, Masson P, Lee R, Goldstein M, Kioko J, Lusi O, Sokal DC. Randomized trial of the Shang Ring for adult male circumcision with removal at one to three weeks: delayed removal leads to detachment. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):e82-9. doi: 10.1097/QAI.0b013e31824ea1f2. — View Citation
Cheng Y, Peng YF, Liu YD, Tian L, Lü NQ, Su XJ, Yan ZJ, Hu JS, Lee R, Kim HH, Sokal DC, Li PS. [A recommendable standard protocol of adult male circumcision with the Chinese Shang Ring: outcomes of 328 cases in China]. Zhonghua Nan Ke Xue. 2009 Jul;15(7):584-92. Chinese. — View Citation
Cheng Y, Wu K, Yan Z, Guo C, Ma J, Su X, Yang S. How to choose appropriate ring size for Shang Ring male circumcision. J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):606-9. doi: 10.1097/QAI.0b013e318273aec9. — View Citation
Cheng Y, Wu K, Yan Z, Yang S, Li F, Su X. Long-term follow-up for Shang Ring male circumcision. Chin Med J (Engl). 2014;127(10):1879-83. — View Citation
Masson P, Li PS, Barone MA, Goldstein M. The ShangRing device for simplified adult circumcision. Nat Rev Urol. 2010 Nov;7(11):638-42. doi: 10.1038/nrurol.2010.167. — View Citation
Pan L, Zhang A, Shen R, Wang Z. Acceptability of early infant male circumcision among Chinese parents: strategy implications of HIV prevention for China. BMC Public Health. 2012 Sep 4;12:738. doi: 10.1186/1471-2458-12-738. — View Citation
Peng YF, Cheng Y, Wang GY, Wang SQ, Jia C, Yang BH, Zhu R, Jian SC, Li QW, Geng DW. Clinical application of a new device for minimally invasive circumcision. Asian J Androl. 2008 May;10(3):447-54. doi: 10.1111/j.1745-7262.2008.00411.x. — View Citation
Wu X, Wang Y, Zheng J, Shen W, Yan JA, Ji H, Li X, Zhang H, Zhou Z. A report of 918 cases of circumcision with the Shang Ring: comparison between children and adults. Urology. 2013 May;81(5):1058-63. doi: 10.1016/j.urology.2012.11.046. — View Citation
Yan B, You H, Zhang K, Tang HY, Mao W, He GH, Yin ZG. [Circumcision with the Chinese Shang Ring in children: outcomes of 824 cases]. Zhonghua Nan Ke Xue. 2010 Mar;16(3):250-3. Chinese. — View Citation
Yue C, Ze-Jun Y, Wu KR, Su XJ, Hu JS, Ma JW, Guo CM, Fang HW, Su R, Zhang Y, Zhang QH. A randomized clinical study of circumcision with a ring device versus conventional circumcision. J Urol. 2012 Nov;188(5):1849-54. doi: 10.1016/j.juro.2012.07.048. Retraction in: J Urol. 2012 Dec;188(6):2443. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain score on the Visual Analog Scale | The pain during and after the two circumcision methods will be compared. Visual Analogue Scale(VAS) will be used to evaluate the pain during operation, 30min post-operatively, 24h post-operatively, ring detachment and during the recovery period. | 28 days | |
Primary | Adverse events | The adverse events such as edema, wound infection, bleeding, unsymmetrical foreskin, wound dehiscence will be recorded. | 3 months | |
Secondary | Time to complete healing | The healing time will be observe by study primary investigator. The usually following time is once a week during the first month and then 3 months later. However, if the wound does not heal completely 28 days post-operatively, the participant will be asked come to visit weekly until complete healing. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03516318 -
Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria
|
N/A | |
Completed |
NCT04653194 -
Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'
|
Phase 3 | |
Completed |
NCT01792570 -
DRV/r + RPV QD: Efficacy and Toxicity Reduction
|
Phase 3 | |
Active, not recruiting |
NCT04826562 -
Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)
|
Phase 4 | |
Completed |
NCT04191967 -
Thermocoagulation for Treatment of Precancerous Cervical Lesions
|
N/A | |
Completed |
NCT02812329 -
Intervention to Encourage HIV Testing and Counseling Among Adolescents
|
Phase 1 | |
Completed |
NCT02919306 -
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
|
Phase 1/Phase 2 | |
Completed |
NCT02516930 -
A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China
|
N/A | |
Completed |
NCT02651376 -
Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT02392884 -
HIV Medication Adherence in Underserved Populations
|
N/A | |
Completed |
NCT01944371 -
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT01778374 -
Mater-Bronx Rapid HIV Testing Project.
|
N/A | |
Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
Completed |
NCT01460433 -
Problems With Immune Recovery in the Gut Tissue
|
N/A | |
Completed |
NCT01076179 -
Kaletra in Combination With Antiretroviral Agents
|
N/A | |
Completed |
NCT01490346 -
Tissue Drug Levels of HIV Medications
|
N/A | |
Completed |
NCT00317460 -
Buprenorphine and Integrated HIV Care
|
Phase 4 | |
Terminated |
NCT04240210 -
Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)
|
Phase 4 | |
Active, not recruiting |
NCT04704336 -
Integration of Hypertension Management Into HIV Care in Nigeria
|
N/A | |
Completed |
NCT03254277 -
3BNC117-LS First-in-Human Phase 1 Study
|
Phase 1 |